On August 30, 2019 Esco Ventures reported the launch of Carmine Therapeutics (Press release, Carmine Therapeutics, AUG 30, 2019, View Source [SID1234567821]). Carmine Therapeutics plans to establish a site in Cambridge, Massachusetts and to expand in the United States at the end of 2019 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Carmine Therapeutics is developing novel types of gene therapies that utilize extracellular vesicles (EVs) produced in the laboratory from red blood cells (RBCs) and that solve many unmet medical needs.

The foundational work behind this revolutionary platform technology was published in 2018 in Nature Communications 9:2359. Red blood cell extracellular vesicles (RBCEVs) are homogeneous, 150-nanometer vesicles that are produced physiologically by RBCs as they age. Several features make RBCEVs an ideal delivery vehicle for gene therapy. First, they are homogenous and can be produced in huge amounts at low cost. Second, RBCs are routinely used for blood transfusion and their secreted vesicles are biocompatible and non-immunogenic. Third, RBCEVs can be frozen and thawed multiple times for long-term storage and can be administered repeatedly without adverse effects. Fourth, RBCEVs have a unique natural biodistribution and can deliver cargoes to several organs in addition to the liver, including bone marrow cells. Lastly, they can be used to target specific cells and tissues using covalently attached peptides or single chain antibodies.

With the REGENT Platform – a proprietary RBCEV isolation, engineering and manufacturing platform of Carmine Therapeutics, we are generating a pipeline of next-generation gene therapies in the areas of hematology, oncology, and immunology.

Using our proprietary technology, RBCEVs can be loaded efficiently with nucleic acids up to 10 kilobases in size and they can deliver their payload efficiently both to cultured cells and to tissues and tumors in vivo. The powerful combination of a robust vector and a unique payload enables us to overcome most of the limitations of existing gene therapies in the clinic. Carmine Therapeutics has exclusively in-licensed and is also developing a comprehensive portfolio of intellectual properties encompassing the key aspects of the REGENT Platform and REGENT product candidates.

On August 30, 2019 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, AUG 30, 2019, View Source [SID1234539173]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird’s 2019 Global Healthcare Conference – New York, September 4-5, 2019

September 4, 9:40 a.m. EDT –Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will deliver a corporate presentation

Citi’s 14th Annual Biotech Conference– Boston, September 5, 2019

Global Summit on Cardiology and Heart Diseases – Dubai, UAE, September 16-17, 2019

September 16, 11:00 a.m. GST –Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver a keynote presentation titled, "Treating hypertriglyceridemic states with RNA interference – emergence of an exciting new modality to treat cardiovascular diseases"

A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

On August 30, 2019 Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, reported the completion of its previously announced registered direct offering of 5,333,334 common shares (or pre-funded warrants to purchase common shares) for an effective price of $0.75 per share with a single healthcare-focused institutional investor (Press release, Sophiris Bio, AUG 30, 2019, View Source [SID1234539157]). In addition to the common shares (or pre-funded warrants to purchase common shares), in a concurrent private placement, Sophiris issued the investor warrants to purchase up to 5,333,334 common shares (the "purchase warrants"), which represent 100% of the number of common shares (or pre-funded warrants to purchase common shares) issued in the registered direct offering, with an exercise price of $0.95 per share and a five-year exercise period commencing six (6) months following the issuance date of such purchase warrants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds to Sophiris from the offering, before deducting the placement agent’s fees and other estimated offering expenses payable by Sophiris, are approximately $4.0 million.

The common shares (or pre-funded warrants to purchase common shares) (but not the purchase warrants or the common shares underlying such purchase warrants) were sold in the registered direct offering by Sophiris pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-219887), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on August 30, 2017. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering has been filed with the SEC and is available on the SEC’s website located at View Source Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [email protected].

The purchase warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the common shares underlying the purchase warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the purchase warrants and underlying common shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On August 30, 2019 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, reported that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:00 p.m. EDT in New York, NY (Press release, Sophiris Bio, AUG 30, 2019, https://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300909439.html [SID1234539156]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophirisbio.com. A replay of the presentation will be available on the Company’s website for 90 days.

On August 30, 2019 Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, reported that management will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019, at the Lotte New York Palace Hotel in New York City (Press release, Amyris Biotechnologies, AUG 30, 2019, https://www.prnewswire.com/news-releases/amyris-to-present-at-hc-wainwright-21st-annual-global-investment-conference-on-september-9-2019-300909518.html [SID1234539155]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Amyris will provide an update on the progress and performance of its business during the presentation, which is scheduled for Monday, September 9, at 9:10 a.m. ET. A live webcast of the presentation including slides and a replay will be available on the investor relations section of the company’s website at View Source